(Added section Abuse Liability - All THR Products) |
|||
| Line 28: | Line 28: | ||
=Abuse Liability - All THR Products= | =Abuse Liability - All THR Products= | ||
===2003: [https://pubmed.ncbi.nlm.nih.gov/12616334/ Subjective effects of the nicotine lozenge: assessment of abuse liability]=== | |||
*In conclusion, results of the present study suggest that abuse liability of nicotine lozenges is low. Low abuse liability of the novel nicotine lozenges is in accordance with current knowledge of consumer use patterns of other, already marketed nicotine replacement therapies, which suggest little abuse of these products once they are marketed. Dose-dependent craving reduction by the lozenges in adults (22–50 years) but not young adults (18–21 years) suggests efficacy of the lozenge for adults, and reinforces the need for further studies of nicotine delivery systems as a treatment for nicotine dependence in younger adults and adolescents | |||
*[https://sci-hub.se/10.1007/s00213-002-1361-2 PDF Version] | |||
*Citation: Houtsmuller, E. J., Henningfield, J. E., & Stitzer, M. L. (2003). Subjective effects of the nicotine lozenge: assessment of abuse liability. Psychopharmacology, 167(1), 20–27. doi:10.1007/s00213-002-1361-2 | |||
*Acknowledgement: This research was supported by SmithKline Beecham Consumer Healthcare. | |||
| Line 36: | Line 43: | ||
*Citation: Houtsmuller, E. J., Fant, R. V., Eissenberg, T. E., Henningfield, J. E., & Stitzer, M. L. (2002). Flavor improvement does not increase abuse liability of nicotine chewing gum. Pharmacology Biochemistry and Behavior, 72(3), 559–568. doi:10.1016/s0091-3057(02)00723-2 | *Citation: Houtsmuller, E. J., Fant, R. V., Eissenberg, T. E., Henningfield, J. E., & Stitzer, M. L. (2002). Flavor improvement does not increase abuse liability of nicotine chewing gum. Pharmacology Biochemistry and Behavior, 72(3), 559–568. doi:10.1016/s0091-3057(02)00723-2 | ||
*Acknowledgement: This study was supported by SmithKline Beecham Consumer Healthcare. | *Acknowledgement: This study was supported by SmithKline Beecham Consumer Healthcare. | ||
=Public Health Advantages / Concerns of Public Health Harms= | =Public Health Advantages / Concerns of Public Health Harms= | ||
edits